The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: A systematic review and meta-analysis.

Maciel MG, Beserra BTS, Oliveira FCB, Ribeiro CM, Coelho MS, Neves FAR, Amato AA

Diabetes research and clinical practice30 May 2018Cited by 29 (Europe PMC)

PMID29857094DOI10.1016/j.diabres.2018.05.034PepBankPUB-29857094

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults, trials of pooled exenatide and liraglutide showed a neutral effect on resting energy expenditure.
In plain wordsIn adults, the GLP-1 drugs exenatide and liraglutide together did not change resting energy use.
Peptide
Liraglutide
Outcome
No significant changeResting energy expenditure with GLP-1 receptor agonists
Study
n = 282
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Source sentences
Summary
Ten trials with exenatide (10 μg bid, for 10-52 weeks) or liraglutide (0.6, 1.2, 1.8 or 3 mg, for 3 days-52 weeks), with a total of 282 participants, indicated a neutral effect of these GLP-1RA on REE, DIT or physical activity-induced EE.
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed, Science Direct and Web of Science were searched for clinical trials investigating the effect of GLP-1 or GLP-1RA on EE in adults.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2985709401
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults, trials of pooled exenatide and liraglutide showed a neutral effect on diet-induced thermogenesis.
In plain wordsIn adults, the GLP-1 drugs exenatide and liraglutide together did not change the energy used to digest food.
Peptide
Liraglutide
Outcome
No significant changeDiet-induced thermogenesis with GLP-1 receptor agonists
Study
n = 282
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Source sentences
Summary
Ten trials with exenatide (10 μg bid, for 10-52 weeks) or liraglutide (0.6, 1.2, 1.8 or 3 mg, for 3 days-52 weeks), with a total of 282 participants, indicated a neutral effect of these GLP-1RA on REE, DIT or physical activity-induced EE.
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed, Science Direct and Web of Science were searched for clinical trials investigating the effect of GLP-1 or GLP-1RA on EE in adults.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2985709402
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults, trials of pooled exenatide and liraglutide showed a neutral effect on physical activity-induced energy expenditure.
In plain wordsIn adults, the GLP-1 drugs exenatide and liraglutide together did not change energy used in physical activity.
Peptide
Liraglutide
Outcome
No significant changePhysical activity-induced energy expenditure with GLP-1 receptor agonists
Study
n = 282
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Source sentences
Summary
Ten trials with exenatide (10 μg bid, for 10-52 weeks) or liraglutide (0.6, 1.2, 1.8 or 3 mg, for 3 days-52 weeks), with a total of 282 participants, indicated a neutral effect of these GLP-1RA on REE, DIT or physical activity-induced EE.
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed, Science Direct and Web of Science were searched for clinical trials investigating the effect of GLP-1 or GLP-1RA on EE in adults.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2985709403
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults, the longest trial of GLP-1 receptor agonists reported a significant increase in resting energy expenditure with exenatide or liraglutide.
In plain wordsIn adults, the longest trial found that exenatide or liraglutide raised resting energy use.
Peptide
Liraglutide
Outcome
IncreaseResting energy expenditure in the longest GLP-1 receptor agonist trial
Study
n: not reported in source
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Source sentences
Summary
the longest trial with GLP-1RA reported a significant increase in REE in response to treatment with both exenatide or liraglutide
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed, Science Direct and Web of Science were searched for clinical trials investigating the effect of GLP-1 or GLP-1RA on EE in adults.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2985709404
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults, most trials reported that weight loss from GLP-1 receptor agonists was not accompanied by decreased resting energy expenditure.
In plain wordsIn adults, weight loss from GLP-1 drugs such as exenatide and liraglutide did not usually lower resting energy use.
Peptide
Liraglutide
Outcome
No significant changeResting energy expenditure during GLP-1 receptor agonist-induced weight loss
Study
n: not reported in source
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Source sentences
Summary
most trials reported that GLP-1RA-induced weight loss was not accompanied by decreased REE.
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed, Science Direct and Web of Science were searched for clinical trials investigating the effect of GLP-1 or GLP-1RA on EE in adults.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2985709405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.